Abstract:Relaxin-3 (also known as INSL7) is a recently identified neuropeptide belonging to the insulin/relaxin superfamily. It has putative roles in the regulation of stress responses, food intake, and reproduction by activation of its cognate G-protein-coupled receptor RXFP3. It also binds and activates the relaxin family peptide receptors RXFP1 and RXFP4 in vitro. To obtain a europium-labeled relaxin-3 as tracer for studying the interaction of these receptors with various ligands, in the present work we propose a novel site-specific labeling strategy for the recombinant human relaxin-3 that has been previously prepared in our laboratory. First, the N-terminal 6 × His-tag of the single-chain relaxin-3 precursor was removed by Aeromonas aminopeptidase and all of the primary amines of the resultant peptide were reversibly blocked by citroconic anhydride. Second, the A-chain N-terminus of the blocked peptide was released by endoproteinase Asp-N cleavage that removed the linker peptide between the B- and A-chains. Third, an alkyne moiety was introduced to the newly released A-chain N-terminus by reaction with the highly active primary amine-specific N-hydroxysuccinimide ester. Fourth, after removal of the reversible blockage under mild acidic condition, europium-loaded DOTA with an azide moiety was introduced to the two-chain relaxin-3 carrying the alkyne moiety through click chemistry. Using this site-specific labeling strategy, homogeneous monoeuropium-labeled human relaxin-3 could be obtained with good overall yield. In contrast, conventional random labeling resulted in a complex mixture that was poorly resolved because human relaxin-3 has four primary amine moieties that all react with the modification reagent. Both saturation and competition binding assays demonstrated that the DOTA/Eu(3+)-labeled relaxin-3 retained high binding affinity for human RXFP3, RXFP4, and RXFP1 and was therefore a suitable non-radioactive and stable tracer to study the interaction of various natural or designed ligands with these receptors. Using this site-specific labeling strategy, other functional probes, such as fluorescent dyes, biotin, or nanoparticles could also be introduced to the A-chain N-terminal of the recombinant human relaxin-3. Additionally, we improved the time-resolved fluorescence assay for the DOTA-bound europium ion which paves the way for the use of DOTA as a lanthanide chelator for protein and peptide labeling in future studies.

Secretory Overexpression and Isotopic Labeling of the Chimeric Relaxin Family Peptide R3/I5 in Pichia Pastoris

Exploring Receptor Selectivity of the Chimeric Relaxin Family Peptide R3/I5 by Incorporating Unnatural Amino Acids.

A Simple Approach for the Preparation of Mature Human Relaxin-3.

A Convenient Method for Europium‐labeling of a Recombinant Chimeric Relaxin Family Peptide R3/I5 for Receptor‐binding Assays

Development of a Selective Agonist for Relaxin Family Peptide Receptor 3

Functionality of an absolutely conserved glycine residue in the chimeric relaxin family peptide R3/I5

Production of human pro-relaxin H2 in the yeast Pichia pastoris

Design, Recombinant Expression and Convenient A‐chain N‐terminal Europium‐labelling of a Fully Active Human Relaxin‐3 Analogue

Development of a Novel Ligand Binding Assay for Relaxin Family Peptide Receptor 3 and 4 Using NanoLuc Complementation

Mechanism for insulin-like peptide 5 distinguishing the homologous relaxin family peptide receptor 3 and 4

Site-specific DOTA/europium-labeling of recombinant human relaxin-3 for receptor-ligand interaction studies

High Expression of Human Relaxin-2 Analogue in Pichia Pastoris and Activity of Expressed Product

Application of the novel bioluminescent ligand–receptor binding assay to relaxin-RXFP1 system for interaction studies

Rapid preparation of bioluminescent tracers for relaxin family peptides using sortase-catalysed ligation

Exploring the Use of Helicogenic Amino Acids for Optimising Single Chain Relaxin-3 Peptide Agonists

Engineering a long acting, non-biased relaxin agonist using Protein-in-Protein technology

Overexpression of Relaxin Family Peptide Receptor 3 in Escherichia Coli and Characterization of Its Ligand Binding Properties

Development of a synthetic relaxin-3/INSL5 chimeric peptide ligand for NanoBiT complementation binding assays

Design, Recombinant Preparation and Europium-Labeling of a Fully Active Easily-Labeled INSL3 Analog for Receptor-Binding Assays

Solid phase synthesis and structural analysis of novel A-chain dicarba analogs of human relaxin-3 (INSL7) that exhibit full biological activity

A Novel BRET-based Binding Assay for Interaction Studies of Relaxin Family Peptide Receptor 3 with Its Ligands